The global market for ubiquitin proteasome research and development was estimated at nearly $2.9 billion in 2013. The market should total more than $5.5 billion by 2018, and have a five-year compound annual growth rate (CAGR) of 14.2% from 2013 to 2018.
This report provides:
- An overview of the state of research tools, diagnostics, and drug discovery in the global ubiquitin proteasome (UPS) research field.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Discussion of existing products in the market.
- Identification of two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets.
- This study notes the trends that are going to affect further drug development in this area.
GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018
Source: BCC Research
Download Report Overview
STUDY GOALS AND OBJECTIVES
This BCC Research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of ubiquitin proteasome market, focusing specifically on research tools, assay development, drug candidates and potential diagnostic applications. It describes existing drug pipelines and scientific platforms on the market, and provides a detailed analysis of the competitive environments, including new potential trends and markets for novel therapies and product development. This study includes information about significant players, trends and obstacles and other information affecting this market and its different sectors.
REASONS FOR DOING THIS STUDY
Ubiquitin proteasome system (UPS) represents one of the most studied and challenging areas in basic and applicable science. Indeed, the scientists who discovered this cellular phenomenon were awarded the Nobel Prize in Chemistry in 2004. Since 2004, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies.
However, despite the accumulation of basic knowledge about the mechanism of action of ubiquitination process and proteasome function, progress in drug screening and therapeutic development has been delayed. However, the proven success of the proteasome inhibitor Velcade (bortezomib) in addition to a recent breakthrough in the identification of new drug candidates in the UPS research field bring new excitement and hope for further successful drug development. Indeed, new second-generation proteasome inhibitor Kyprolis was recently approved by the FDA.
Moreover, the real commercial potential of this research area has not yet been fully acknowledged. Therefore, this study will provide knowledge of the current state of drug discovery in this field and new technologies in assay development and, more importantly, will describe potential novel commercial venues in diagnostics and drug development.
Overall, this report highlights the main segments in the ubiquitin proteasome market: reagents and technological platforms required for the research, drug discovery pipelines and potential applications of UPS in different areas of industry. It discusses its major players, current and future trends, and influences. Drivers and challenges in each segment of this industry are described in detail, including forecasts for the next five years.
SCOPE AND FORMAT
This report is essentially a business tool that can help market players evaluate properly new commercial opportunities in the ubiquitin proteasome space especially in the drug discovery, diagnostics and research tools submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment and forecasts market growth, future trends and product development in every major segment of this market.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted.
In a second phase, a series of semi-structured interviews was conducted with company representatives, bench scientists, marketing representatives and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology and consulting companies. Subsequent analysis of the documents and interviews notes was iterative.
This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for ubiquitin proteasome drug discovery, diagnostics and research tools applications. It provides insight into the market position of major companies and shows new opportunities otherwise overlooked or less known to the business community.
Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in biochemistry, cell biology and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Subscribe to any of BCC Research’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Download Report Overview